{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T01:24:29Z","timestamp":1786929869264,"version":"build-2736575974"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82371945"],"award-info":[{"award-number":["No. 82371945"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"DOI":"10.1186\/s12880-026-02482-1","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T16:14:39Z","timestamp":1781108079000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Microstructural MRI combined with metabolic MRI to evaluate the progression-free survival of patients with glioblastoma at the early follow-up after tumor treating fields: a pilot study"],"prefix":"10.1186","volume":"26","author":[{"given":"Jue","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XinLi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"issue":"8","key":"2482_CR1","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","volume":"17","author":"PY Wen","year":"2020","unstructured":"Wen PY, Weller M, Lee EQ, et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol Aug. 2020;17(8):1073\u2013113. https:\/\/doi.org\/10.1093\/neuonc\/noaa106.","journal-title":"Neuro Oncol Aug"},{"issue":"4","key":"2482_CR2","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.ijrobp.2020.06.020","volume":"15","author":"JA Bovi","year":"2020","unstructured":"Bovi JA, Prah MA, Retzlaff AA, et al. Pulsed Reduced Dose Rate Radiotherapy in Conjunction With Bevacizumab or Bevacizumab Alone in Recurrent High-grade Glioma: Survival Outcomes. Int J Radiat Oncol Biol Phys Nov. 2020;15(4):979\u201386. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.06.020.","journal-title":"Int J Radiat Oncol Biol Phys Nov"},{"key":"2482_CR3","doi-asserted-by":"publisher","unstructured":"Wefel JS, Armstrong TS, Pugh SL, et al. Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG\/RTOG 0825). Neuro Oncol. Jul 1 2021;23(7):1125\u20131138. https:\/\/doi.org\/10.1093\/neuonc\/noab011.","DOI":"10.1093\/neuonc\/noab011"},{"issue":"6","key":"2482_CR4","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/JCO.22.00164","volume":"20","author":"CI Tsien","year":"2023","unstructured":"Tsien CI, Pugh SL, Dicker AP, et al. NRG Oncology\/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma. J Clin Oncol Feb. 2023;20(6):1285\u201395. https:\/\/doi.org\/10.1200\/JCO.22.00164.","journal-title":"J Clin Oncol Feb"},{"issue":"23","key":"2482_CR5","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","volume":"19","author":"R Stupp","year":"2017","unstructured":"Stupp R, Taillibert S, Kanner A, et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA Dec. 2017;19(23):2306\u201316. https:\/\/doi.org\/10.1001\/jama.2017.18718.","journal-title":"JAMA Dec"},{"issue":"23","key":"2482_CR6","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1001\/jama.2015.16669","volume":"15","author":"R Stupp","year":"2015","unstructured":"Stupp R, Taillibert S, Kanner AA, et al. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA Dec. 2015;15(23):2535\u201343. https:\/\/doi.org\/10.1001\/jama.2015.16669.","journal-title":"JAMA Dec"},{"issue":"5","key":"2482_CR7","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.ijrobp.2021.12.152","volume":"1","author":"M Glas","year":"2022","unstructured":"Glas M, Ballo MT, Bomzon Z, et al. The Impact of Tumor Treating Fields on Glioblastoma Progression Patterns. Int J Radiat Oncol Biol Phys Apr. 2022;1(5):1269\u201378. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.12.152.","journal-title":"Int J Radiat Oncol Biol Phys Apr"},{"issue":"20","key":"2482_CR8","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1158\/0008-5472.CAN-22-0887","volume":"17","author":"JC Moser","year":"2022","unstructured":"Moser JC, Salvador E, Deniz K, et al. The Mechanisms of Action of Tumor Treating Fields. Cancer Res Oct. 2022;17(20):3650\u20138. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-0887.","journal-title":"Cancer Res Oct"},{"issue":"3","key":"2482_CR9","doi-asserted-by":"publisher","first-page":"e14563","DOI":"10.1111\/cns.14563","volume":"30","author":"A Yu","year":"2024","unstructured":"Yu A, Zeng J, Yu J, Cao S, Li A. Theory and application of TTFields in newly diagnosed glioblastoma. CNS Neurosci Ther Mar. 2024;30(3):e14563. https:\/\/doi.org\/10.1111\/cns.14563.","journal-title":"CNS Neurosci Ther Mar"},{"key":"2482_CR10","doi-asserted-by":"publisher","unstructured":"Lee J, Grabowski MM, Lathia JD. Tumor treating fields: killing two birds with one stone. J Clin Invest Apr 2022;15(8). https:\/\/doi.org\/10.1172\/JCI159073.","DOI":"10.1172\/JCI159073"},{"issue":"8","key":"2482_CR11","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/s41419-022-05127-7","volume":"18","author":"S Xu","year":"2022","unstructured":"Xu S, Luo C, Chen D, Tang L, Chen L, Liu Z. Whole transcriptome and proteome analyses identify potential targets and mechanisms underlying tumor treating fields against glioblastoma. Cell Death Dis Aug. 2022;18(8):721. https:\/\/doi.org\/10.1038\/s41419-022-05127-7.","journal-title":"Cell Death Dis Aug"},{"key":"2482_CR12","doi-asserted-by":"publisher","unstructured":"Chen D, Le SB, Hutchinson TE, et al. Tumor treating fields dually activate STING and AIM2 inflammasomes to induce adjuvant immunity in glioblastoma. J Clin Invest Apr 2022;15(8). https:\/\/doi.org\/10.1172\/JCI149258.","DOI":"10.1172\/JCI149258"},{"issue":"8","key":"2482_CR13","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/s41416-024-02608-8","volume":"130","author":"Q Cao","year":"2024","unstructured":"Cao Q, Hajosch A, Kast RE, et al. Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro. Br J Cancer May. 2024;130(8):1365\u201376. https:\/\/doi.org\/10.1038\/s41416-024-02608-8.","journal-title":"Br J Cancer May"},{"issue":"1","key":"2482_CR14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.neo.2020.11.003","volume":"23","author":"CB Patel","year":"2021","unstructured":"Patel CB, Beinat C, Xie Y, Chang E, Gambhir SS. Tumor treating fields (TTFields) impairs aberrant glycolysis in glioblastoma as evaluated by (18)FDASA-23, a non-invasive probe of pyruvate kinase M2 (PKM2) expression. Neoplasia Jan. 2021;23(1):58\u201367. https:\/\/doi.org\/10.1016\/j.neo.2020.11.003.","journal-title":"Neoplasia Jan"},{"issue":"4","key":"2482_CR15","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3322\/caac.21613","volume":"70","author":"AC Tan","year":"2020","unstructured":"Tan AC, Ashley DM, Lopez GY, Malinzak M, Friedman HS, Khasraw M. Management of glioblastoma: State of the art and future directions. CA Cancer J Clin Jul. 2020;70(4):299\u2013312. https:\/\/doi.org\/10.3322\/caac.21613.","journal-title":"CA Cancer J Clin Jul"},{"issue":"33","key":"2482_CR16","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1200\/JCO.23.01059","volume":"20","author":"PY Wen","year":"2023","unstructured":"Wen PY, van den Bent M, Youssef G, et al. RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. J Clin Oncol Nov. 2023;20(33):5187\u201399. https:\/\/doi.org\/10.1200\/JCO.23.01059.","journal-title":"J Clin Oncol Nov"},{"issue":"9","key":"2482_CR17","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.1016\/S1470-2045(24)00130-X","volume":"25","author":"P Karschnia","year":"2024","unstructured":"Karschnia P, Gerritsen JKW, Teske N, et al. The oncological role of resection in newly diagnosed diffuse adult-type glioma defined by the WHO 2021 classification: a Review by the RANO resect group. Lancet Oncol Sep. 2024;25(9):e404\u201319. https:\/\/doi.org\/10.1016\/S1470-2045(24)00130-X.","journal-title":"Lancet Oncol Sep"},{"issue":"2","key":"2482_CR18","doi-asserted-by":"publisher","first-page":"e230793","DOI":"10.1148\/radiol.230793","volume":"310","author":"I Wamelink","year":"2024","unstructured":"Wamelink I, Azizova A, Booth TC, et al. Brain Tumor Imaging without Gadolinium-based Contrast Agents: Feasible or Fantasy? Radiology Feb. 2024;310(2):e230793. https:\/\/doi.org\/10.1148\/radiol.230793.","journal-title":"Radiology Feb"},{"issue":"7","key":"2482_CR19","doi-asserted-by":"publisher","first-page":"918","DOI":"10.2967\/jnumed.120.254243","volume":"1","author":"G Ceccon","year":"2021","unstructured":"Ceccon G, Lohmann P, Werner JM, et al. Early Treatment Response Assessment Using (18)F-FET PET Compared with Contrast-Enhanced MRI in Glioma Patients After Adjuvant Temozolomide Chemotherapy. J Nucl Med Jul. 2021;1(7):918\u201325. https:\/\/doi.org\/10.2967\/jnumed.120.254243.","journal-title":"J Nucl Med Jul"},{"issue":"3","key":"2482_CR20","doi-asserted-by":"publisher","first-page":"748","DOI":"10.3171\/2022.12.JNS222173","volume":"1","author":"JS Young","year":"2023","unstructured":"Young JS, Al-Adli N, Scotford K, Cha S, Berger MS. Pseudoprogression versus true progression in glioblastoma: what neurosurgeons need to know. J Neurosurg Sep. 2023;1(3):748\u201359. https:\/\/doi.org\/10.3171\/2022.12.JNS222173.","journal-title":"J Neurosurg Sep"},{"issue":"1","key":"2482_CR21","doi-asserted-by":"publisher","first-page":"e240343","DOI":"10.1148\/radiol.240343","volume":"313","author":"L Zhang","year":"2024","unstructured":"Zhang L, Long X, Chen L, et al. Detecting Cellular Microstructural Changes of Liver Fibrosis with Time-Dependent Diffusion MRI. Radiology Oct. 2024;313(1):e240343. https:\/\/doi.org\/10.1148\/radiol.240343.","journal-title":"Radiology Oct"},{"issue":"3","key":"2482_CR22","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1148\/radiol.211180","volume":"303","author":"D Wu","year":"2022","unstructured":"Wu D, Jiang K, Li H, et al. Time-Dependent Diffusion MRI for Quantitative Microstructural Mapping of Prostate Cancer. Radiology Jun. 2022;303(3):578\u201387. https:\/\/doi.org\/10.1148\/radiol.211180.","journal-title":"Radiology Jun"},{"issue":"1","key":"2482_CR23","doi-asserted-by":"publisher","first-page":"e240288","DOI":"10.1148\/radiol.240288","volume":"313","author":"X Wang","year":"2024","unstructured":"Wang X, Ba R, Huang Y, et al. Time-Dependent Diffusion MRI Helps Predict Molecular Subtypes and Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer. Radiology Oct. 2024;313(1):e240288. https:\/\/doi.org\/10.1148\/radiol.240288.","journal-title":"Radiology Oct"},{"issue":"3","key":"2482_CR24","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1002\/mrm.25684","volume":"75","author":"XY Jiang","year":"2016","unstructured":"Jiang XY, Li H, Xie JP, Zhao P, Gore JC, Xu JZ. Quantification of cell size using temporal diffusion spectroscopy. Magnetic Reson Medicine Mar. 2016;75(3):1076\u201385. https:\/\/doi.org\/10.1002\/mrm.25684.","journal-title":"Magnetic Reson Medicine Mar"},{"issue":"6","key":"2482_CR25","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1002\/mrm.28056","volume":"83","author":"J Xu","year":"2020","unstructured":"Xu J, Jiang X, Li H, et al. Magnetic resonance imaging of mean cell size in human breast tumors. Magn Reson Med Jun. 2020;83(6):2002\u201314. https:\/\/doi.org\/10.1002\/mrm.28056.","journal-title":"Magn Reson Med Jun"},{"issue":"2","key":"2482_CR26","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/mrm.28454","volume":"85","author":"J Xu","year":"2021","unstructured":"Xu J, Jiang X, Devan SP, et al. MRI-cytometry: Mapping nonparametric cell size distributions using diffusion MRI. Magn Reson Med Feb. 2021;85(2):748\u201361. https:\/\/doi.org\/10.1002\/mrm.28454.","journal-title":"Magn Reson Med Feb"},{"issue":"19","key":"2482_CR27","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1158\/0008-5472.CAN-21-2929","volume":"4","author":"SP Devan","year":"2022","unstructured":"Devan SP, Jiang X, Luo G, et al. Selective Cell Size MRI Differentiates Brain Tumors from Radiation Necrosis. Cancer Res Oct. 2022;4(19):3603\u201313. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-2929.","journal-title":"Cancer Res Oct"},{"key":"2482_CR28","doi-asserted-by":"publisher","unstructured":"Hoffmann E, Gerwing M, Niland S, et al. Profiling specific cell populations within the inflammatory tumor microenvironment by oscillating-gradient diffusion-weighted MRI. J Immunother Cancer. Mar 2023;11(3) https:\/\/doi.org\/10.1136\/jitc-2022-006092.","DOI":"10.1136\/jitc-2022-006092"},{"issue":"6","key":"2482_CR29","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1093\/neuonc\/noad003","volume":"2","author":"H Zhang","year":"2023","unstructured":"Zhang H, Liu K, Ba R, et al. Histological and molecular classifications of pediatric glioma with time-dependent diffusion MRI-based microstructural mapping. Neuro Oncol Jun. 2023;2(6):1146\u201356. https:\/\/doi.org\/10.1093\/neuonc\/noad003.","journal-title":"Neuro Oncol Jun"},{"issue":"5","key":"2482_CR30","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1002\/mrm.29758","volume":"90","author":"A Zhu","year":"2023","unstructured":"Zhu A, Shih R, Huang RY, et al. Revealing tumor microstructure with oscillating diffusion encoding MRI in pre-surgical and post-treatment glioma patients. Magn Reson Med Nov. 2023;90(5):1789\u2013801. https:\/\/doi.org\/10.1002\/mrm.29758.","journal-title":"Magn Reson Med Nov"},{"key":"2482_CR31","doi-asserted-by":"publisher","unstructured":"Figini M, Castellano A, Bailo M, et al. Comprehensive brain tumour characterisation with VERDICT-MRI: evaluation of cellular and vascular measures validated by histology. Cancers (Basel) Apr 2023;27(9). https:\/\/doi.org\/10.3390\/cancers15092490.","DOI":"10.3390\/cancers15092490"},{"issue":"2","key":"2482_CR32","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1148\/radiol.2020191376","volume":"295","author":"JE Park","year":"2020","unstructured":"Park JE, Kim HS, Park SY, Jung SC, Kim JH, Heo HY. Identification of Early Response to Anti-Angiogenic Therapy in Recurrent Glioblastoma: Amide Proton Transfer-weighted and Perfusion-weighted MRI compared with Diffusion-weighted MRI. Radiology May. 2020;295(2):397\u2013406. https:\/\/doi.org\/10.1148\/radiol.2020191376.","journal-title":"Radiology May"},{"key":"2482_CR33","doi-asserted-by":"publisher","first-page":"109694","DOI":"10.1016\/j.radonc.2023.109694","volume":"184","author":"N von Knebel Doeberitz","year":"2023","unstructured":"von Knebel Doeberitz N, Kroh F, Breitling J, et al. CEST imaging of the APT and ssMT predict the overall survival of patients with glioma at the first follow-up after completion of radiotherapy at 3T. Radiother Oncol Jul. 2023;184:109694. https:\/\/doi.org\/10.1016\/j.radonc.2023.109694.","journal-title":"Radiother Oncol Jul"},{"issue":"1","key":"2482_CR34","doi-asserted-by":"publisher","first-page":"e190036","DOI":"10.1148\/rycan.2020190036","volume":"2","author":"S Okuchi","year":"2020","unstructured":"Okuchi S, Hammam A, Golay X, Kim M, Thust S. Endogenous Chemical Exchange Saturation Transfer MRI for the Diagnosis and Therapy Response Assessment of Brain Tumors: A Systematic Review. Radiol Imaging Cancer Jan. 2020;2(1):e190036. https:\/\/doi.org\/10.1148\/rycan.2020190036.","journal-title":"Radiol Imaging Cancer Jan"},{"issue":"7","key":"2482_CR35","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1007\/s00259-022-05676-1","volume":"49","author":"L Mancini","year":"2022","unstructured":"Mancini L, Casagranda S, Gautier G, et al. CEST MRI provides amide\/amine surrogate biomarkers for treatment-naive glioma sub-typing. Eur J Nucl Med Mol Imaging Jun. 2022;49(7):2377\u201391. https:\/\/doi.org\/10.1007\/s00259-022-05676-1.","journal-title":"Eur J Nucl Med Mol Imaging Jun"},{"issue":"1","key":"2482_CR36","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1093\/neuonc\/noad150","volume":"5","author":"KS Patel","year":"2024","unstructured":"Patel KS, Yao J, Cho NS, et al. pH-Weighted amine chemical exchange saturation transfer echo planar imaging visualizes infiltrating glioblastoma cells. Neuro Oncol Jan. 2024;5(1):115\u201326. https:\/\/doi.org\/10.1093\/neuonc\/noad150.","journal-title":"Neuro Oncol Jan"},{"key":"2482_CR37","doi-asserted-by":"publisher","unstructured":"Essed RA, Prysiazhniuk Y, Wamelink IJ, Azizova A, Keil VC. Performance of amide proton transfer imaging to differentiate true progression from therapy-related changes in gliomas and metastases. Eur Radiol Aug. 2024;12. https:\/\/doi.org\/10.1007\/s00330-024-11004-y.","DOI":"10.1007\/s00330-024-11004-y"},{"issue":"4","key":"2482_CR38","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1002\/mrm.27569","volume":"81","author":"A Deshmane","year":"2019","unstructured":"Deshmane A, Zaiss M, Lindig T, et al. 3D gradient echo snapshot CEST MRI with low power saturation for human studies at 3T. Magn Reson Med Apr. 2019;81(4):2412\u201323. https:\/\/doi.org\/10.1002\/mrm.27569.","journal-title":"Magn Reson Med Apr"},{"key":"2482_CR39","doi-asserted-by":"publisher","unstructured":"Jenkins EPW, Finch A, Gerigk M, Triantis IF, Watts C, Malliaras GG. Electrotherapies for glioblastoma. Adv Sci Sep 2021;8(18) https:\/\/doi.org\/10.1002\/advs.202100978.","DOI":"10.1002\/advs.202100978"},{"issue":"7","key":"2482_CR40","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s00262-020-02534-7","volume":"69","author":"T Voloshin","year":"2020","unstructured":"Voloshin T, Kaynan N, Davidi S, et al. Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy. Cancer Immunol Immun Jul. 2020;69(7):1191\u2013204. https:\/\/doi.org\/10.1007\/s00262-020-02534-7.","journal-title":"Cancer Immunol Immun Jul"},{"key":"2482_CR41","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.trsl.2019.10.003","volume":"217","author":"NK Karanam","year":"2020","unstructured":"Karanam NK, Ding LH, Aroumougame A, Story MD. Tumor treating fields cause replication stress and interfere with DNA replication fork maintenance: Implications for cancer therapy. Transl Res Mar. 2020;217:33\u201346. https:\/\/doi.org\/10.1016\/j.trsl.2019.10.003.","journal-title":"Transl Res Mar"},{"issue":"1","key":"2482_CR42","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/14737159.2022.2017283","volume":"2","author":"PJ Hong","year":"2022","unstructured":"Hong PJ, Kudulaiti N, Wu S, Nie JT, Zhuang DX. Tumor treating fields: a comprehensive overview of the underlying molecular mechanism. Expert Rev Mol Diagn Jan. 2022;2(1):19\u201328. https:\/\/doi.org\/10.1080\/14737159.2022.2017283.","journal-title":"Expert Rev Mol Diagn Jan"},{"key":"2482_CR43","doi-asserted-by":"publisher","unstructured":"Xu SC, Luo CK, Chen DK, et al. circMMD reduction following tumor treating fields inhibits glioblastoma progression through FUBP1\/FIR\/DVL1 and miR-15b-5p\/FZD6 signaling. J Exp Clin Canc Res. Mar 17 2023;42(1) https:\/\/doi.org\/10.1186\/s13046-023-02642-z.","DOI":"10.1186\/s13046-023-02642-z"},{"key":"2482_CR44","doi-asserted-by":"publisher","unstructured":"Miller R, Song AD, Ali A, et al. Scalp-sparing radiation with concurrent temozolomide and tumor treating fields (SPARE) for patients with newly diagnosed glioblastoma. Front Oncol. Apr 29 2022;12. https:\/\/doi.org\/10.3389\/fonc.2022.896246.","DOI":"10.3389\/fonc.2022.896246"},{"key":"2482_CR45","doi-asserted-by":"crossref","unstructured":"Tran DD, Ghiaseddin AP, Chen DD, Le SB. Final analysis of 2-THE-TOP: a phase 2 study of TTFields (Optune) plus pembrolizumab plus maintenance temozolomide (TMZ) in patients with newly diagnosed glioblastoma. J Clin Oncol Jun 1 2023;41(16).","DOI":"10.1200\/JCO.2023.41.16_suppl.2024"},{"key":"2482_CR46","doi-asserted-by":"publisher","unstructured":"Liu YF, Zhu WZ, Zhu HQ, et al. Characterization of orthotopic xenograft tumor of glioma stem cells (GSCs) on MRI, PET and immunohistochemical staining. Front Oncol. Dec 15 2022;12. https:\/\/doi.org\/10.3389\/fonc.2022.1085015.","DOI":"10.3389\/fonc.2022.1085015"},{"key":"2482_CR47","doi-asserted-by":"publisher","unstructured":"Bartkowiak T, Lima SM, Hayes MJ, et al. An immunosuppressed microenvironment distinguishes lateral ventricle-contacting glioblastomas. JCI Insight Jun 2023;22(12). https:\/\/doi.org\/10.1172\/jci.insight.160652.","DOI":"10.1172\/jci.insight.160652"},{"issue":"5","key":"2482_CR48","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.cell.2021.01.022","volume":"4","author":"ND Mathewson","year":"2021","unstructured":"Mathewson ND, Ashenberg O, Tirosh I, et al. Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. Cell Mar. 2021;4(5):1281\u2013e129826. https:\/\/doi.org\/10.1016\/j.cell.2021.01.022.","journal-title":"Cell Mar"},{"issue":"2","key":"2482_CR49","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s11060-020-03661-y","volume":"151","author":"RW Chan","year":"2021","unstructured":"Chan RW, Chen H, Myrehaug S, et al. Quantitative CEST and MT at 1.5T for monitoring treatment response in glioblastoma: early and late tumor progression during chemoradiation. J Neurooncol Jan. 2021;151(2):267\u201378. https:\/\/doi.org\/10.1007\/s11060-020-03661-y.","journal-title":"J Neurooncol Jan"},{"key":"2482_CR50","doi-asserted-by":"publisher","unstructured":"Park SW, Lai JHC, Han X, et al. Preclinical application of CEST MRI to detect early and regional tumor response to local brain tumor treatment. Pharmaceutics Jan 2024;12(1). https:\/\/doi.org\/10.3390\/pharmaceutics16010101.","DOI":"10.3390\/pharmaceutics16010101"},{"issue":"2","key":"2482_CR51","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/mrm.27751","volume":"82","author":"S Goerke","year":"2019","unstructured":"Goerke S, Soehngen Y, Deshmane A, et al. Relaxation-compensated APT and rNOE CEST-MRI of human brain tumors at 3 T. Magn Reson Med Aug. 2019;82(2):622\u201332. https:\/\/doi.org\/10.1002\/mrm.27751.","journal-title":"Magn Reson Med Aug"},{"key":"2482_CR52","doi-asserted-by":"publisher","unstructured":"Borges de Almeida G, Pascuzzo R, Mambrin F, et al. The role of amide proton transfer (APT)-weighted imaging in glioma: assessment of tumor grading, molecular profile and survival in different tumor components. Cancers (Basel) Aug. 2024;29(17). https:\/\/doi.org\/10.3390\/cancers16173014.","DOI":"10.3390\/cancers16173014"},{"key":"2482_CR53","doi-asserted-by":"publisher","unstructured":"Lohmann P, Elahmadawy MA, Gutsche R, et al. FET PET Radiomics for differentiating pseudoprogression from early tumor progression in glioma patients post-chemoradiation. Cancers Dec 2020;12(12) https:\/\/doi.org\/10.3390\/cancers12123835.","DOI":"10.3390\/cancers12123835"},{"issue":"11","key":"2482_CR54","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1002\/cncr.32790","volume":"1","author":"H Akbari","year":"2020","unstructured":"Akbari H, Rathore S, Bakas S, et al. Histopathology-validated machine learning radiographic biomarker for noninvasive discrimination between true progression and pseudo-progression in glioblastoma. Cancer-Am Cancer Soc Jun. 2020;1(11):2625\u201336. https:\/\/doi.org\/10.1002\/cncr.32790.","journal-title":"Cancer-Am Cancer Soc Jun"},{"issue":"1","key":"2482_CR55","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-021-01102-5","volume":"12","author":"XC Ding","year":"2021","unstructured":"Ding XC, Wang LL, Zhang XD, et al. The relationship between expression of PD-L1 and HIF-1alpha in glioma cells under hypoxia. J Hematol Oncol Jun. 2021;12(1):92. https:\/\/doi.org\/10.1186\/s13045-021-01102-5.","journal-title":"J Hematol Oncol Jun"},{"issue":"1","key":"2482_CR56","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1186\/s13046-023-02927-3","volume":"15","author":"HJ Yun","year":"2023","unstructured":"Yun HJ, Li M, Guo D, et al. AMPK-HIF-1alpha signaling enhances glucose-derived de novo serine biosynthesis to promote glioblastoma growth. J Exp Clin Cancer Res Dec. 2023;15(1):340. https:\/\/doi.org\/10.1186\/s13046-023-02927-3.","journal-title":"J Exp Clin Cancer Res Dec"},{"key":"2482_CR57","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.mri.2020.06.018","volume":"72","author":"T MAEKAWA","year":"2020","unstructured":"MAEKAWA T, HORI M, MURATA K, et al. Differentiation of high-grade and low-grade intra-axial brain tumors by time-dependent diffusion MRI[J]. Magn Reson Imaging. 2020;72:34\u201341. https:\/\/doi.org\/10.1016\/j.mri.2020.06.018.","journal-title":"Magn Reson Imaging"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12880-026-02482-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-026-02482-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-026-02482-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:31:51Z","timestamp":1786926711000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12880-026-02482-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2482"],"URL":"https:\/\/doi.org\/10.1186\/s12880-026-02482-1","relation":{},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"19 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study adhered to the declaration of Helsinki and received approval from the Institutional Review Board of our institution (Wuhan Union Hospital, NO. UHCT22438). Written informed consent was obtained from all patients in this study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Peng Sun is employee of Neusoft Medical Systems Co. Ltd (Shenyang, China). The remaining authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"404"}}